Researchers study drug for Alzheimer's stem cell treatment

04/24/2006 | United Press International

U.S. researchers say Axonyx's Posiphen was found to improve the ability of transplanted human neuronal stem cells to change into neurons in biotech mice. They say the Phase I trial drug appears to suppress the amyloid precursor protein, allowing new neurons to be produced in the brain, a critical development toward a stem cell therapy for Alzheimer's.

View Full Article in:

United Press International

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC